M7T Price sensitive 27 Feb 2026, 8:57 AM

First Half FY26 Result

MACH7 Technologies Ltd

Mach7 Technologies Reports First Half FY26 Results

Key points

  • Expanded product suite with Flamingo architecture; first contract secured in December 2025
  • Recurring revenue of A$11.6M, 85% of total revenue; 78% coverage of OPEX
  • Total revenue of A$13.7M, down 23% on pcp largely due to fewer one-off capital licence deals

Full summary

Mach7 Technologies Limited (ASX:M7T), a healthcare software company, has reported its half year results for the six months ended 31 December 2025. The company's first half FY26 revenue was A$13.7M, 23% lower than the prior corresponding period, largely due to lower one-off capital software licence revenue, a reduction in recurring revenue following customer churn, and lower professional services revenue. However, recurring revenue accounted for 85% of total revenue and coverage of operating expenditure was 78% in H1 FY26. Operating expenses of A$14.8M were 6% lower on the prior corresponding period, mainly due to lower employment expenses and the realisation of operating efficiencies across the business. Adjusted EBITDA of -A$2.3M (H1 FY25: A$0.8M) was lower on the prior corresponding period as the lack of one-off capital software sales more than offset the reduction in operating costs. NPATA of -A$2.7M (H1 FY25: A$1.4) and NPAT of -A$5.7M (H1 FY25: -A$1.9M) were also lower on the prior corresponding period largely due to the revenue decline in H1 FY26. Mach7's financial position remains strong with no debt and A$18.5M cash on hand at 31 December 2025.

Outlook

Mach7 continues to be a leading innovator in the enterprise imaging space, with a portfolio of interoperable solutions. As provider consolidation reshapes the healthcare landscape, Mach7 is well positioned to capitalise on these shifts, supported by a strong installed base and the continued global adoption of enterprise imaging. The company remains focused on disciplined cost management while selectively investing in growth-critical capabilities across sales execution, product development and platform scalability, including a significantly expanded marketing program to modernise its brand and market engagement. Underpinned by a re-energised sales and partner model and early traction for its Flamingo solutions, Mach7 remains confident in its ability to deliver against its strategy and capture emerging market opportunities.

Summary generated by a large language model. Please interpret with care.

Sign in for more about this company, including guidance changes and other insights.
Sign in